- Home
- TIXT vs XERS Comparison
TIXT vs XERS Comparison
Compare TIXT & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIXT
- XERS
- Stock Information
- Founded
- TIXT 2005
- XERS 2005
- Country
- TIXT Canada
- XERS United States
- Employees
- TIXT N/A
- XERS N/A
- Industry
- TIXT EDP Services
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- TIXT Technology
- XERS Health Care
- Exchange
- TIXT Nasdaq
- XERS Nasdaq
- Market Cap
- TIXT 694.9M
- XERS 628.7M
- IPO Year
- TIXT 2021
- XERS 2018
- Fundamental
- Price
- TIXT $2.71
- XERS $5.01
- Analyst Decision
- TIXT Hold
- XERS Strong Buy
- Analyst Count
- TIXT 8
- XERS 6
- Target Price
- TIXT $4.44
- XERS $6.25
- AVG Volume (30 Days)
- TIXT 232.0K
- XERS 2.3M
- Earning Date
- TIXT 05-09-2025
- XERS 05-08-2025
- Dividend Yield
- TIXT N/A
- XERS N/A
- EPS Growth
- TIXT N/A
- XERS N/A
- EPS
- TIXT N/A
- XERS N/A
- Revenue
- TIXT $2,671,000,000.00
- XERS $222,551,000.00
- Revenue This Year
- TIXT $3.72
- XERS $31.75
- Revenue Next Year
- TIXT $3.63
- XERS $21.09
- P/E Ratio
- TIXT N/A
- XERS N/A
- Revenue Growth
- TIXT N/A
- XERS 29.88
- 52 Week Low
- TIXT $2.13
- XERS $1.72
- 52 Week High
- TIXT $7.74
- XERS $6.07
- Technical
- Relative Strength Index (RSI)
- TIXT 57.76
- XERS 59.63
- Support Level
- TIXT $2.46
- XERS $4.26
- Resistance Level
- TIXT $2.64
- XERS $5.28
- Average True Range (ATR)
- TIXT 0.11
- XERS 0.28
- MACD
- TIXT 0.04
- XERS 0.09
- Stochastic Oscillator
- TIXT 61.54
- XERS 78.91
About TIXT TELUS International (Cda) Inc. Subordinate Voting Shares
TELUS International (Cda) Inc is a digital customer experience innovator that designs, builds, and delivers next-generation solutions. Its clients include companies across several verticals, including Tech and Games, eCommerce and FinTech, Banking, Financial Services and Insurance, Communications and Media, and Healthcare. The solutions offered by the company include Digital Experience, Customer Experience, Advisory Services, and Back Office and Automation among other services. Geographically, it derives a majority of its revenue from the European region.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).